Yohann Loriot, MD, PhD, Gustave Roussy Institute & University of Paris-Saclay, Paris, France, discusses LEAP-011, a Phase III study of first-line pembrolizumab plus lenvatinib in patients with advanced urothelial carcinoma (UC) ineligible for platinum-based chemotherapy. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

свернуть